Harbor BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer | Associated press
CAMBRIDGE, Mass. And ROTTERDAM, The Netherlands and SUZHOU, China, July 20, 2021 / PRNewswire / – Harbor BioMed (“HBM”, HKEX: 02142) announced the appointment of Dr. Yingying Chen as Chief Financial Officer (CFO). Dr Chen will be responsible for leading the overall management of finance and investor relations and overseeing all aspects of financial operations. She will provide leadership and management of the company’s financial planning, business strategy, funding management, cash management, internal control, budgeting and investor relations. She is expected to manage HBM’s financial and business activities and to develop and maintain relationships with existing and potential investors.
Dr Chen joins HBM with over 20 years of experience and outstanding achievements in the finance and healthcare industries. Prior to joining HBM, she stepped down as Managing Director, Head of Healthcare at GF Investments Hong Kong Limited (the offshore investment platform of Guangfa Securities) and CMBC International Holdings Ltd. (a wholly owned subsidiary of China Minsheng Bank). Previously, she worked in several investment banks, including UBS, Royal Bank of Scotland / ABN AMRO Bank and Deutsche Bank AG, where she served clients in the healthcare sector. During her previous career, she had also worked as a research scientist at Pfizer’s global R&D center.
Dr Chen holds a PhD in Chemical Engineering from the University of Minnesota, an MBA from the University of Michigan, and a BA in Chemistry and Engineering Physics from the University of Miami.
About Harbor BioMed
Harbor BioMed (HKEX: 02142) is a global biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic antibodies focused on oncology and immunology. The Company builds its solid portfolio and differentiated pipeline through internal R&D capabilities, collaborations with co-discovery and co-development partners and selected acquisitions.
The company’s proprietary antibody technology platforms, Harbor Mice®, generate fully human monoclonal antibodies in two heavy chain and two light chain formats (H2L2), as well as heavy chain only format (HCAb). Based on anti-HCAb antibodies, HCAb-based immune cell activators (HBICE ™) are capable of producing tumor-killing effects not achievable by traditional combination therapies. Integrating Harbor Mice® with a unique B cell cloning platform, our antibody discovery engine is very unique and efficient for the development of next generation therapeutic antibodies.
For more information, please visit www.harbourbiomed.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/harbour-biomed-appoints-yingying-chen-phd-as-chief-financial-officer-301337520.html
SOURCE Port BioMed
Copyright © 2021 PR Newswire Association LLC. All rights reserved.